Expression of ER, PgR, HER1, HER2, and response: A study of preoperative chemotherapy

Annals of Oncology

Volumn 19, Issue 3, 2008, Pages 465-472

  Colleoni, Marco ^a   Viale, G ^a,b   Zahrieh, D ^c   Bottiglieri, L ^a   Gelber, R D ^c   Veronesi, P ^a,b   Balduzzi, A ^a   Torrisi, R ^a   Luini, A ^a,b   Intra, M ^a   Dellapasqua, S ^a   Cardillo, A ^a   Ghisini, R ^a   Peruzzotti, G ^a   Goldhirsch, A ^a  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

Breast cancer; Predictive factors; Primary chemotherapy; Prognostic factors

Indexed keywords

ANTHRACYCLINE DERIVATIVE; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; NAVELBINE; PROGESTERONE RECEPTOR; TAXANE DERIVATIVE;

ARTICLE; BREAST BIOPSY; BREAST CANCER; CANCER GRADING; CANCER REGRESSION; CANCER STAGING; CONFIDENCE INTERVAL; CORRELATION ANALYSIS; DISEASE FREE SURVIVAL; ECHOMAMMOGRAPHY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MULTIPLE REGRESSION; MULTIVARIATE ANALYSIS; PATHOLOGY; PREDICTION; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; STATISTICAL SIGNIFICANCE; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; UNIVARIATE ANALYSIS;

EID: 40149100006     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdm509     Document Type: Article

References (30)

1. B. Fisher N. Gunduz E.A. Saffer Influence of the interval between primary tumor removal and chemotherapy on kinetics and growth of metastasis Cancer Res 43 1983 1488 1492
2. A.E. Ring I.E. Smith S. Ashley Oestrogen receptor status, pathological complete response and prognosis in patients receiving neoadjuvant chemotherapy for early breast cancer Br J Cancer 91 2004 2012 2017
3. M. Kaufmann G. von Minckwitz R. Smith International expert panel on the use of primary (preoperative) systemic treatment of operable breast cancer: review and recommendations J Clin Oncol 21 2003 2600 2608
4. M. Colleoni G. Viale D. Zahrieh Chemotherapy is more effective in patients with breast cancer not expressing steroid hormone receptors: a study of preoperative treatment Clin Cancer Res 10 2004 6622 6628
5. T. Petit C. Borel J. Ghnassia Chemotherapy response of breast cancer depends on HER-2 status and anthracycline dose intensity in the neoadjuvant setting Clin Cancer Res 7 2001 1577 1581
6. D.F. Hayes A.D. Thor L.G. Dressler HER2 and response to paclitaxel in node-positive breast cancer N Engl J Med 357 2007 1496 1506
7. J. Mendelsohn J. Baselga Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer J Clin Oncol 21 2003 2787 2799
8. T.A. Bucholz T.U. Xyaiou K. Kiang Ang Epidermal growth factor receptor expression correlates with poor survival in patients who have breast carcinoma treated with doxorubicin-based neoadjuvant chemotherapy Cancer 104 2005 676 681
9. G. Arpino H. Weiss A. Lee Estrogen receptor positive, progesterone receptor-negative breast cancer: correlation with growth factor receptor expression and tamoxifen resistance J Natl Cancer Inst 97 2005 1254 1261
10. M. Dowsett C. Harper-Wynne I. Boeddinghaus HER-2 amplification impedes the antiproliferative effects of hormone therapy in estrogen receptor-positive primary breast cancer Cancer Res 61 2001 8452 8458
11. H.M. Kuerer L.A. Newman T.M. Smith Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy J Clin Oncol 17 1999 460 469
12. A.S. Knoop S.M. Bentzen M.M. Nielsen Value of epidermal growth factor receptor, HER2, p53, and steroid receptors in predicting the efficacy of tamoxifen in high-risk postmenopausal breast cancer patients J Clin Oncol 19 2001 3376 3384
13. M. Dowsett J. Houghton C. Iden Benefit from adjuvant tamoxifen therapy in primary breast cancer patients according oestrogen receptor, progesterone receptor, EGF receptor and HER2 status Ann Oncol 17 2006 818 826
14. R. Torrisi V. Bagnardi G. Pruneri Antitumour and biological effects of letrozole and GnRH analogue as primary therapy in premenopausal women with ER and PgR positive locally advanced operable breast cancer Br J Cancer 97 2007 802 808
15. M. Kaufmann G. von Minckwitz H.D. Bear Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: new perspectives 2006 Ann Oncol 2007 In press
16. M. Colleoni S. Gelber A.S. Coates Influence of endocrine-related factors on response to perioperative chemotherapy for patients with node-negative breast cancer J Clin Oncol 19 2001 4141 4149
17. S. Gruvberger M. Ringner Y. Chen Estrogen receptor status in breast cancer is associated with remarkably distinct gene expression patterns Cancer Res 61 2001 5979 5984
18. P.J. Barrett-Lee Growth factor signalling in clinical breast cancer and its impact on response to conventional therapies: a review of chemotherapy Endocr Relat Cancer 12 2005 125 133
19. V. Guarneri K. Broglio S.W. Kau Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors J Clin Oncol 24 2006 1037 1044
20. R.K. Gregory T.J. Powles J. Salter Prognostic relevance of cerbB2 expression following neoadjuvant chemotherapy in patients in a randomised trial of neoadjuvant versus adjuvant chemoendocrine therapy Breast Cancer Res Treat 59 2000 171 175
21. M.J. Piccart-Gebhart M. Procter B. Leyland-Jones Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer N Engl J Med 353 2005 1659 1672
22. A.U. Buzdar V. Valero N.K. Ibrahim Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: an update of the initial randomized study population and data of additional patients treated with the same regimen Clin Cancer Res 13 2007 228 233
23. T. Sorlie C.M. Perou R. Tibshirani Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications Proc Natl Acad Sci U S A 98 2001 10869 10874
24. S. Cleator W. Heller R.C. Coombes Triple-negative breast cancer: therapeutic options Lancet Oncol 8 2007 235 244
25. T.O. Nielsen F.D. Hsu K. Jensen Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma Clin Cancer Res 10 2004 5367 5374
26. G. Konecny G. Pauletti M. Pegram Quantitative association between HER2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer J Natl Cancer Inst 95 2004 142 153
27. M. Colleoni N. Rotmensz G. Martinelli Lesson learned from high-dose chemotherapy for high-risk breast cancer (What you see is what you mean) Ann Oncol 15 2004 355 356
28. E.M. Cormier M.F. Wolf V.C. Jordan Decrease in estradiol-stimulated progesterone receptor production in MCF-7 cells by epidermal growth factor and possible clinical implication for paracrine-regulated breast cancer growth Cancer Res 49 1989 576 580
29. H.J. Kim X. Cui S.G. Hilsenbeck Progesterone receptor loss correlates with human epidermal growth factor receptor 2 overexpression in estrogen receptor positive breast cancer Clin Cancer Res 12 2006 1013 1018
30. J.M. Gee J.F. Robertson E. Gutteridge Epidermal growth factor receptor/HER2/insulin-like growth factor receptor signalling and oestrogen receptor activity in clinical breast cancer Endocr Relat Cancer 12 2005 99 111